Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR

IRB/UVA Tracking #
20667
Contact First Name

Gracie Tubbs Hockenberry

Contact Email
Contact Phone
Phase
II
Primary purpose
Treatment
Cancer PI
Richard Hall
Status
OPEN TO ACCRUAL